Видео ютуба по тегу Medicines: Cevostamab

Talquetamab, cevostamab and CAR-T in the future treatment of myeloma
Talquetamab, cevostamab and CAR-T in the future treatment of myeloma
Cevostamab - Guest Lecture #myeloma
Cevostamab - Guest Lecture #myeloma
Cevostamab Update | Therapies on the Horizon #myeloma
Cevostamab Update | Therapies on the Horizon #myeloma
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
Up-and-coming therapies: talquetamab & cevostamab
Up-and-coming therapies: talquetamab & cevostamab
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
Clinical activity and safety of cevostamab in relapsed/refractory multiple myeloma
Outcomes of patients with myeloma receiving fixed-duration cevostamab
Outcomes of patients with myeloma receiving fixed-duration cevostamab
Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024
Cevostamab, a FcRH5 bispecific antibody, for RRMM | Joshua Richter, MD | #ASH2024
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Bispecific antibodies in multiple myeloma: teclistamab, talquetamab, and cevostamab
Cevostamab in RRMM Patients: CAMMA 2 Study Results | Joshua Richter, MD | EHA 2024
Cevostamab in RRMM Patients: CAMMA 2 Study Results | Joshua Richter, MD | EHA 2024
Tocilizumab pre-treatment reduced cytokine release syndrome in RRMM pts receiving cevostamab.
Tocilizumab pre-treatment reduced cytokine release syndrome in RRMM pts receiving cevostamab.
Cevostamab (BFCR4350A): a novel bispecific antibody in R/R myeloma therapy
Cevostamab (BFCR4350A): a novel bispecific antibody in R/R myeloma therapy
Safety & efficacy of cevostamab in patients with heavily pre-treated R/R multiple myeloma
Safety & efficacy of cevostamab in patients with heavily pre-treated R/R multiple myeloma
The efficacy of cevostamab in R/R multiple myeloma and the importance of bispecific antibodies
The efficacy of cevostamab in R/R multiple myeloma and the importance of bispecific antibodies
Cevostamab in patients with heavily pretreated R/R myeloma: updated results from a Phase I trial
Cevostamab in patients with heavily pretreated R/R myeloma: updated results from a Phase I trial
Enduring responses following cevostamab therapy in R/R multiple myeloma
Enduring responses following cevostamab therapy in R/R multiple myeloma
Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results
Cevostamab Shows Promise in Hard-to-Treat Multiple Myeloma: Early CAMMA 2 Trial Results
KarMMa-4: ide-cel for newly diagnosed high-risk multiple myeloma
KarMMa-4: ide-cel for newly diagnosed high-risk multiple myeloma
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Going beyond BCMA-targeting agents in myeloma: GPRC5D and FcRH5-targeting therapies
Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute
Bispecific Antibodies in Multiple Myeloma | Dana-Farber Cancer Institute